New Small-Scale Expression Packages: RushMab- Ready in just 8 days! LEARN MORE

Biointron - Antibody Discovery, Antibody Production, Stable cell line, Protein Expression, CRO

Antibody Antibody Antibody

Services & Products

About Us

  • 0 +
    Years of Experience
  • 0 +
    Employees
  • 0 +
    Companies Served Globally
  • 0 +
    Delivered Annually

Why you should choose us

  • Pioneering Antibody Solutions

    We specialize in antibody expression, discovery, and optimization with internationally recognized automated production standards - offering superior services at market- competitive rates with efficient turnaround times.

  • Unique Cell Line Commercialization

    We possess exclusive re-licensing rights for the commercialization of the CHO-K1BN cell line licensed from ECACC.

  • Global Collaborative Excellence

    Our partnerships with over 1,500 global biotech and pharmaceutical entities, coupled with our collaborative advancements in international clinical stages, solidify our esteemed position in the industry.

  • Trust and Exclusive ownership

    We commit to complete confidentiality - preserving the exclusive ownership rights of the antibodies we produce for our clients.

Antibody

Engage with Biointron, your dependable partner for efficient, affordable, and top-tier custom antibody solutions.

About Biointron

Founded in 2012, and certified to ISO 9001:2015, Biointron is a CRO (Contract research organization) specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.


Biointron is a leading high-throughput recombinant antibody/protein expression and discovery service provider. From gene sequence to purified antibodies, it just takes 2 weeks. Biointron has delivered tens of thousands of recombinant antibodies for more than 1,500 biotech and pharma companies all over the world.

Read More Read More

Client Voices: Biointron Success Stories

Learn from our partners and clients about the transformative impact of Biointron's expertise.

"We evaluated the 6 proteins you produced for us and we were quite pleased by the results. our internal assessments of the molecules are very encouraging so we would like to potentially expand this further."

— AstraZeneca

"We have tested both batches of the antibodies you sent us. They're active and give comparable results with little batch to batch variation."

— AbbVie

"Excellent.The protein quality and activity was high and up to our standards, we appreciate the help and the work.The short timeline for the production is the main factor Biointron differs from other CROs."

— Moderna

"Great working with you, I've been highly impressed and recommending you to many in my network."

— Sanofi

"I just wanted to give you a quick heads-up regarding the expression we conducted at Biointron. Essentially, everything went well and was super fast, so we are all very much satisfied."

— Merck KGaA

"BioIntron was the best from the three: it was the only company that was able to express all the sequences and the yield for those proteins that the other two companies also could express was, generally, higher."

— ImmuVia, LLC

Our Latest News and Stories

Bispecific antibodies are rapidly transforming the therapeutic landscape, especially in oncology and autoimmune diseases. Such recombinant molecules can bind to two different antigens at the same time, offering greater specificity in targeting disease pathways. Since their introduction, the area of bispecifics has held tremendous promise in oncological cancers like multiple myeloma and lymphomas.

In vitro display technologies are a group of methods used to display diverse antibody libraries on the surface of solid supports or particles like phage, yeast, ribosomes, and bacteria. They are powerful tools for the discovery and engineering of novel antibodies with desired binding properties and were first explored for antibody selection over 30 years ago.

Oct 12, 2024
Blog

Chimeric antibodies, formed by combining the variable regions of one species with the constant domains of another, are essential for various research fields, especially in vivo and in vitro studies. These hybrid antibodies maintain their antigen-binding specificity while offering flexibility in different research settings. This flexibility makes them highly valuable for biotherapeutic research, immunoassays, and diagnostic applications.

Oct 11, 2024
Blog

In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#

Mar 23, 2024
Company News

Biointron is proud to announce a strategic partnership with FatiAbGen, a leading biotechnology firm focused on antibody-based therapeutics. As the newly appointed Korean distributor for Biointron, FatiAbGen will be at the forefront of delivering Biointron’s products to the Korean market.

Mar 15, 2024
Company News

Celebrate International Women's Day with Biointron's female workforce!

Mar 15, 2024
Company News

Time: October 15 - 17, 2024
Location: Basel, Switzerland

Time: October 21 - 23, 2024
Location: Kyoto, Japan
Booth: #15

Time: November 5 - 7, 2024
Location: Barcelona, Spain
Booth: #1102

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.